ADIL: מכפיל PEG Adial

Adial Pharmaceuticals is developing the ethical brand AD04, gaining the trust of patients. The integration of the drug into psychiatric care expands the alcoholism treatment ecosystem. However, logistical risks from Asia could slow down research. The growth-adjusted P/E ratio demonstrates the asset's value dynamics, and the current figure has settled at 0.00, which helps assess the company's potential relative to profit growth rates.

Adial Pharmaceuticals focuses on developing addiction treatments, attracting leading neurobiologists through an RSU system and scientific autonomy. The PEG ratio, which compares the P/E ratio to earnings growth rates, determines the fairness of market value relative to business expansion; analyzing this P/E dynamics relative to earnings growth on GURU.Markets allows for the identification of undervalued assets when the value is below one.